Discovery Award – HT9425-23-PRMRP-DA
- up to USD$200,000 over 2 years
- supports the exploration of a highly innovative new concept or untested theory
- Letter of Intent due 29 March 2023
Investigator-Initiated Research Award HT9425-23-PRMRP-IIRA
- up to USD$1.6M over 4 years for single investigators; USD$2.0M for partnering investigators
- supports Supports research that will make an original and important contribution to the field of research or patient care in the 2023 Topic Area(s) of interest.
- Letters of Intent due 19 April 2023
Technology/Therapeutic Development Award HT9425-23-PRMRP-TTDA
- up to USD$2M over 4 years (funding level 1) or USD$4M over 4 years (funding level 2)
- supports translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life
- Supports product-oriented projects (eg device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
- Clinical trials will not be funded
- Letters of Intent due 19 April 2023
Clinical Trial Award – HT9425-23-PRMRP-CTA
- up to USD$500,000 over 18 months for Planning Phase plus undefined amount for clinical trial over 4 years; or
- undefined amount for clinical trial over 4 years
- Supports rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the 2023 Topic Areas of interest
- Planning Phase option provides support to prepare and submit an Investigational New Drug/ Investigational Device Exemption (IND/ IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded.
- Pre-proposal due 12 April 2023
Lifestyle and Behavioral Health Interventions and Research Award – HT9425-23-PRMRP-LIBRA
- up to USD$3M over 4 years
- Supports development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes.
- Projects may include clinical research or clinical trials for interventions that do not require regulation by the FDA.
- Encourages patient advocate participation in the research team
- Letters of Intent due 19 April 2023
Focused Program Award – HT9425-23-PRMRP-FPA
- up to USD$7.2M over 4 years
- Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.
- Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
- Projects may range from exploratory/ hypothesis-developing studies through small-scale clinical trials that together will address the overarching goal/question.
- Research team of highly qualified, multidisciplinary project leaders should be led by an investigator with demonstrated success in directing large, focused projects.
- Pre-applications due 12 April 2023
2023 PRMRP Topic Areas and Strategic Goals cover foundational studies, prevention, diagnosis, treatment and epidemiology regarding diseases, disorders and injuries within the following broad areas :
- autoimmune disorders & immunology
- cardiovascular health
- hemorrhage control and blood products
- infectious diseases
- internal medicine
- neuroscience
- orthopaedic medicine
- rare-diseases and conditions
- respiratory health
